Editor's Note: This column marks Adam Feuerstein's return to TheStreet.com. Feuerstein is an award-winning reporter who worked at TheStreet.com before a two-year stint covering biotech at a New York-based investment firm. We're thrilled to welcome him back.

The annual JPMorgan Chase health care conference, which rolls into San Francisco next week, is always a bit of a madhouse -- companies big and small selling their newly minted 2007 investment stories to an overflowing crowd.

This granddaddy of biotech investment confabs (you're a veteran if you remember when it was run by Hambrecht & Quist) is like the Detroit auto show of life sciences, minus the scantily clad booth babes.

But for all its occasional bluster and hassle, the JPMorgan conference is a good show because it sets the stage for biotech investing for the next 12 months. I don't necessarily find it the best forum for deep research, but I usually walk away with a good overview of the sector and a bunch of interesting investment ideas in my notebook.

I'll be there, as will my colleague Marc Lichtenfeld, so check back here for in-depth coverage. With the conference as a backdrop, here are some (but not all) of the 2007 biotech story lines making waves on my radar screen:

Gilead Sciences ( GILD) has earned its status on the biotech sector A team because of its strong, market-leading HIV drug franchise. Last year's successful launch of Atripla, the first-ever single-pill, once-daily treatment for HIV, cemented that reputation.

But in 2007, investors are looking beyond Gilead's core business (which is still growing at a very healthy clip, by the way) and focusing more on how the company aims to digest last year's $2.5 billion acquisition of Myogen. When the deal was announced in October, some on Wall Street were a bit uneasy with Gilead's decision to shift from its strength in infectious diseases into pulmonary disease. The hefty price tag on the Myogen deal also raised some eyebrows.

If you liked this article you might like


Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio